Quick Answer
Autolus Therapeutics plc reported Research And Development Expense of $117.69 million for the year ending 2025.
- Autolus Therapeutics plc showed a decrease of -15.0% in Research And Development Expense from 2024 to 2025.
- This data is from Autolus Therapeutics plc's annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: $5.56 million | Q4 2018: $17.71 million | Q1 2022: $28.37 million | Q2 2022: $30.79 million | Q3 2022: $31.49 million | Q1 2023: $27.39 million | Q2 2023: $33.23 million | Q3 2023: $32.32 million | Q1 2024: $30.67 million | Q2 2024: $36.61 million | Q3 2024: $40.32 million | Q1 2025: $26.73 million | Q2 2025: $27.43 million | Q3 2025: $27.89 million.
- Over the full 10 years of available data (2016 to 2025), Autolus Therapeutics plc's Research And Development Expense has grown by 1,027.7%.
- Historical annual values: Fiscal year 2025: $117.69 million | Fiscal year 2024: $138.44 million | Fiscal year 2023: $130.48 million | Fiscal year 2022: $117.35 million | Fiscal year 2021: $110.84 million | Fiscal year 2020: $134.89 million | Fiscal year 2019: $105.42 million | Fiscal year 2018: $36.15 million | Fiscal year 2017: $16.01 million | Fiscal year 2016: $10.44 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: